BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Addiction. 2012 Sep;107(9):1621-9. doi: 10.1111/j.1360-0443.2012.03870.x. Epub 2012 May 8.
To identify dose-tapering strategies associated with sustained success following methadone maintenance treatment (MMT).
Population-based retrospective cohort study.
Linked administrative medication dispensation data from British Columbia, Canada.
From 25 545 completed MMT episodes, 14 602 of which initiated a taper, 4183 individuals (accounting for 4917 MMT episodes) from 1996 to 2006 met study inclusion criteria.
The primary outcome was sustained successful taper, defined as a daily dose ≤5 mg per day in the final week of the treatment episode and no treatment re-entry, opioid-related hospitalization or mortality within 18 months following episode completion.
The overall rate of sustained success was 13% among episodes meeting inclusion criteria (646 of 4917), 4.4% (646 of 14 602) among all episodes initiating a taper and 2.5% (646 of 25 545) among all completed episodes in the data set. The results of our multivariate logistic regression analyses suggested that longer tapers had substantially higher odds of success [12-52 weeks versus <12 weeks: odds ratio (OR): 3.58; 95% confidence interval (CI): 2.76-4.65; >52 weeks versus <12 weeks: OR: 6.68; 95% CI: 5.13-8.70], regardless of how early in the treatment episode the taper was initiated, and a more gradual, stepped tapering schedule, with dose decreases scheduled in only 25-50% of the weeks of the taper, provided the highest odds of sustained success (versus <25%: OR: 1.61; 95% CI: 1.22-2.14).
The majority of patients attempting to taper from methadone maintenance treatment will not succeed. Success is enhanced by gradual dose reductions interspersed with periods of stabilization. These results can inform the development of a more refined guideline for future clinical practice.
确定与美沙酮维持治疗(MMT)后持续成功相关的剂量递减策略。
基于人群的回顾性队列研究。
加拿大不列颠哥伦比亚省的链接管理药物配给数据。
从 25545 个完成的 MMT 疗程中,有 14602 个开始递减剂量,从 1996 年到 2006 年,有 4183 个人(占 4917 个 MMT 疗程)符合研究纳入标准。
主要结局是持续成功的递减剂量,定义为治疗疗程最后一周每天的剂量≤5 毫克,并且在疗程结束后 18 个月内没有重新接受治疗、与阿片类药物相关的住院或死亡。
符合纳入标准的疗程中持续成功的总体比例为 13%(4917 例中的 646 例),所有开始递减剂量的疗程中为 4.4%(14602 例中的 646 例),所有完成疗程的疗程中为 2.5%(25545 例中的 646 例)。我们的多变量逻辑回归分析结果表明,较长的递减剂量有更高的成功几率[12-52 周与<12 周:比值比(OR):3.58;95%置信区间(CI):2.76-4.65;>52 周与<12 周:OR:6.68;95% CI:5.13-8.70],无论递减开始得有多早,并且更渐进、更有步骤的递减方案,即仅在递减疗程的 25-50%的周中安排剂量减少,提供了持续成功的最高几率(与<25%相比:OR:1.61;95% CI:1.22-2.14)。
大多数试图从美沙酮维持治疗中逐渐减少剂量的患者都不会成功。逐渐减少剂量并穿插稳定期可以提高成功率。这些结果可以为未来临床实践中制定更精细的指南提供信息。